Impact Biomedical, Inc. Financials
This page shows Impact Biomedical, Inc. (IBO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Impact Biomedical, Inc. has an operating margin of -13381.3%, meaning the company retains $-13381 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Impact Biomedical, Inc. carries a low D/E ratio of 0.15, meaning only $0.15 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
Impact Biomedical, Inc.'s current ratio of 0.35 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 1/100, which could limit financial flexibility.
Impact Biomedical, Inc. generates a -93.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -580.1% the prior year.
Impact Biomedical, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Impact Biomedical, Inc. generates $0.16 in operating cash flow (-$1.9M OCF vs -$11.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Impact Biomedical, Inc. earns $-5.4 in operating income for every $1 of interest expense (-$4.3M vs $793K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Impact Biomedical, Inc. generated $32K in revenue in fiscal year 2025.
Impact Biomedical, Inc.'s EBITDA was -$3.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 88.6% from the prior year.
Impact Biomedical, Inc. reported -$11.8M in net income in fiscal year 2025. This represents an increase of 52.1% from the prior year.
Impact Biomedical, Inc. earned $-0.38 per diluted share (EPS) in fiscal year 2025. This represents an increase of 83.5% from the prior year.
Cash & Balance Sheet
Impact Biomedical, Inc. held $3K in cash against $0 in long-term debt as of fiscal year 2025.
Impact Biomedical, Inc. had 105M shares outstanding in fiscal year 2025. This represents an increase of 809.4% from the prior year.
Margins & Returns
Impact Biomedical, Inc.'s gross margin was -1225.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
Impact Biomedical, Inc.'s operating margin was -13381.3% in fiscal year 2025, reflecting core business profitability.
Impact Biomedical, Inc.'s net profit margin was -36993.8% in fiscal year 2025, showing the share of revenue converted to profit.
Impact Biomedical, Inc.'s ROE was -93.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 486.3 percentage points from the prior year.
Capital Allocation
Impact Biomedical, Inc. invested $340K in research and development in fiscal year 2025. This represents an increase of 22.3% from the prior year.
IBO Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $18K+157.1% | $7K | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | $1K-90.9% | $11K | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $17K+525.0% | -$4K | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $52K-30.7% | $75K-27.2% | $103K | N/A | $82K-32.2% | $121K-33.9% | $183K |
| SG&A Expenses | N/A | $261K+6.1% | $246K-0.8% | $248K | N/A | $132K-9.0% | $145K-2.0% | $148K |
| Operating Income | N/A | -$948K+17.8% | -$1.2M-14.2% | -$1.0M | N/A | -$1.1M-80.0% | -$626K+18.8% | -$771K |
| Interest Expense | N/A | $262K+0.8% | $260K-4.1% | $271K | N/A | $305K+16.9% | $261K+13.5% | $230K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$1.5M+89.8% | -$14.3M-1032.3% | -$1.3M | N/A | $4.2M+577.7% | -$889K+7.6% | -$962K |
| EPS (Diluted) | N/A | $-0.12 | $-1.18-972.7% | $-0.11 | N/A | $0.06+166.7% | $-0.09+10.0% | $-0.10 |
IBO Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $17.4M-4.4% | $18.2M-4.5% | $19.1M-4.9% | $20.1M-1.2% | $20.3M-56.5% | $46.7M+5.8% | $44.1M-0.5% | $44.4M |
| Current Assets | $411K-55.2% | $917K-38.1% | $1.5M-32.2% | $2.2M-10.8% | $2.4M-22.9% | $3.2M+934.2% | $307K-8.4% | $335K |
| Cash & Equivalents | $3K-75.0% | $12K-98.1% | $624K-52.7% | $1.3M-34.1% | $2.0M-25.1% | $2.7M+133300.0% | $2K0.0% | $2K |
| Inventory | $63K-87.0% | $485K-0.2% | $486K-0.6% | $489K | N/A | N/A | N/A | N/A |
| Accounts Receivable | $5K-66.7% | $15K | N/A | $4K | N/A | N/A | $128K0.0% | $128K |
| Goodwill | N/A | N/A | N/A | N/A | $25.1M0.0% | $25.1M0.0% | $25.1M0.0% | $25.1M |
| Total Liabilities | $1.9M-93.2% | $27.1M+2.3% | $26.4M+99.7% | $13.2M+1.4% | $13.1M+5.7% | $12.3M-40.5% | $20.7M+3.2% | $20.1M |
| Current Liabilities | $1.2M-95.1% | $23.8M+2.7% | $23.2M+132.3% | $10.0M+1.9% | $9.8M+759.8% | $1.1M-92.2% | $14.5M+4.6% | $13.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $12.6M+206.8% | -$11.8M-14.2% | -$10.3M-369.1% | $3.8M-9.8% | $4.3M-86.4% | $31.3M+34.1% | $23.4M-3.7% | $24.3M |
| Retained Earnings | -$49.5M+9.6% | -$54.8M-2.8% | -$53.3M-36.8% | -$38.9M-3.4% | -$37.7M-256.7% | -$10.6M+28.7% | -$14.8M-6.4% | -$13.9M |
IBO Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $99K+116.2% | -$613K+11.7% | -$694K-1.8% | -$682K+30.8% | -$986K+1.5% | -$1.0M-160.0% | -$385K+20.1% | -$482K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $1K0.0% | $1K | $0-100.0% | $1K | $0-100.0% | $1K | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A | N/A | $317K-91.4% | $3.7M+854.7% | $384K-20.5% | $483K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
IBO Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 94.4%+151.6pp | -57.1% | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | -5266.7%+11204.8pp | -16471.4% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | -8166.7%+196776.2pp | -204942.9% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | -33.0% | N/A | 13.6%+17.4pp | -3.8%+0.2pp | -4.0% |
| Return on Assets | N/A | -8.1%+67.2pp | -75.3%-69.0pp | -6.3% | N/A | 9.1%+11.1pp | -2.0%+0.2pp | -2.2% |
| Current Ratio | 0.35+0.3 | 0.04-0.0 | 0.06-0.2 | 0.22-0.0 | 0.25-2.5 | 2.79+2.8 | 0.020.0 | 0.02 |
| Debt-to-Equity | 0.15+2.4 | -2.29+0.3 | -2.56-6.0 | 3.45+0.4 | 3.06+2.7 | 0.39-0.5 | 0.89+0.1 | 0.83 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: The current ratio is below 1.0 (0.35), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Impact Biomedical, Inc.'s annual revenue?
Impact Biomedical, Inc. (IBO) reported $32K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Impact Biomedical, Inc. profitable?
No, Impact Biomedical, Inc. (IBO) reported a net income of -$11.8M in fiscal year 2025, with a net profit margin of -36993.8%.
What is Impact Biomedical, Inc.'s EBITDA?
Impact Biomedical, Inc. (IBO) had EBITDA of -$3.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Impact Biomedical, Inc.'s gross margin?
Impact Biomedical, Inc. (IBO) had a gross margin of -1225.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Impact Biomedical, Inc.'s operating margin?
Impact Biomedical, Inc. (IBO) had an operating margin of -13381.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Impact Biomedical, Inc.'s net profit margin?
Impact Biomedical, Inc. (IBO) had a net profit margin of -36993.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Impact Biomedical, Inc.'s return on equity (ROE)?
Impact Biomedical, Inc. (IBO) has a return on equity of -93.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Impact Biomedical, Inc.'s operating cash flow?
Impact Biomedical, Inc. (IBO) generated -$1.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Impact Biomedical, Inc.'s total assets?
Impact Biomedical, Inc. (IBO) had $17.4M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Impact Biomedical, Inc. spend on research and development?
Impact Biomedical, Inc. (IBO) invested $340K in research and development during fiscal year 2025.
What is Impact Biomedical, Inc.'s current ratio?
Impact Biomedical, Inc. (IBO) had a current ratio of 0.35 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Impact Biomedical, Inc.'s debt-to-equity ratio?
Impact Biomedical, Inc. (IBO) had a debt-to-equity ratio of 0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Impact Biomedical, Inc.'s return on assets (ROA)?
Impact Biomedical, Inc. (IBO) had a return on assets of -68.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Impact Biomedical, Inc.'s cash runway?
Based on fiscal year 2025 data, Impact Biomedical, Inc. (IBO) had $3K in cash against an annual operating cash burn of $1.9M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Impact Biomedical, Inc.'s Piotroski F-Score?
Impact Biomedical, Inc. (IBO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Impact Biomedical, Inc.'s earnings high quality?
Impact Biomedical, Inc. (IBO) has an earnings quality ratio of 0.16x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Impact Biomedical, Inc. cover its interest payments?
Impact Biomedical, Inc. (IBO) has an interest coverage ratio of -5.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Impact Biomedical, Inc.?
Impact Biomedical, Inc. (IBO) scores 25 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.